Suven Life Sciences, Eli Lilly for drug discovery

Mumbai, Aug 30: Suven Life Sciences Ltd today announced that it has signed an agreement with Eli Lilly and Co, a US based global pharmaceutical company to collaborate on the pre-clinical research of molecules in the therapeutic area of central nervous system disorder (CNS).

Commenting on the collaboration, Mr Ramakrishna Nirogi, Vice President, Drug Discovery of the company said,this effort is a collaboration between Suven and Lilly, with scientists from both parties working together in a team, with the goal of identifying potent, oral compounds that selectively modulate the specified G-Protein coupled receptor for the target CNS disease, The company will receive payments from Lilly and potentially downstream payments if the identified candidates are selected by Lilly for further pre-clinical research and development.

This is our first true research collaboration with a global pharmaceutical company, thereby helping us realize the next step of our strategic visionsaid Venkat Jasti, Vice Chairman and CEO of the company.

Suvens business model has expanded from contract research and manufacturing services (CRAMS) to drug discovery and development support services (DDDSS) and now to collaborative research (CRP).

UNI